Research programme - T cell receptor-based cancer therapeutics - Bellicum Pharmaceuticals/Leiden University Medical CenterAlternative Names: High-affinity T cell receptor product candidates - Bellicum Pharmaceuticals/LUMC; TCR cell therapies - Bellicum Pharmaceuticals/LUMC; TCRs - Bellicum Pharmaceuticals/Leiden University Medical Center
Latest Information Update: 09 Jun 2016
At a glance
- Originator Bellicum Pharmaceuticals; Leiden University Medical Center
- Developer Leiden University Medical Center
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunostimulants; T lymphocyte replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Cancer